Blocking TGFBR2 signaling in mGSCs, through both molecular and pharmacological methods, counters this GSC-mediated immunosuppression, predicting that TGFBR2 blockades could cooperate with current immunotherapy to enhance anti-tumor effects in GBM. Here, TGFBR2 is linked to glioblastoma.